New Delhi : Ranbaxy Laboratories declined to comment on reports from Brussels that European Union anti-trust regulators may fine it for allegedly blocking the entry of cheaper generic medicines in the EU. Reports said that Ranbaxy was among the nine companies that are to be fined. When contacted, a Ranbaxy spokesperson said: “We will not like to offer any comments at this point”. Other firms named in the reports were Denmark’s Lundbeck, Merck KGaA, Generics UK, Arrow, Resolution Chemicals, Xellia Pharmaceuticals, Alpharma and AL Industriers. Shares of Ranbaxy fell by 3.49% to end at Rs 362.35 apiece at the BSE on Monday.
EU regulators may fine Ranbaxy and other drug makers
RECENT STORIES
Lack Of Clear Decision-Making Is Crippling Pakistan’s Economy: Report
BHEL Shelves Varanasi Plant Plan As Board Reassesses Capital Investment Strategy
Havells India Q3 Profit Rises 8% YoY To ₹300 Crore, Revenue Jumps 17% Sequentially
IMF Raises India’s GDP Growth Forecast To 7.3 Per Cent For FY26 On Strong Economic Momentum
Rupee Breaches 91/USD Mark 2nd Time In A Month, Ends 14 Paise Lower At 90.92 Against US Dollar
